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Background/aim: While mortality rates decrease in many chronic diseases, it continues to increase in COPD. This situation has led
to the need to develop new approaches such as phenotypes in the management of COPD. We aimed to investigate the distribution,
characteristics and treatment preference of COPD phenotypes in Turkey.
Materials and methods: The study was designed as a national, multicenter, observational and cross-sectional. A total of 1141 stable
COPD patients were included in the analysis.
Results: The phenotype distribution was as follows: 55.7% nonexacerbators (NON-AE), 25.6% frequent exacerbators without
chronic bronchitis (AE NON-CB), 13.9% frequent exacerbators with chronic bronchitis (AE-CB), and 4.8% with asthma and COPD
overlap (ACO). The FEV1 values were significantly higher in the ACO and NON-AE than in the AE-CB and AE NON-CB (p <
0.001). The symptom scores, ADO (age, dyspnoea and FEV1) index and the rates of exacerbations were significantly higher in the
AE-CB and AE NON-CB phenotypes than in the ACO and NON-AE phenotypes (p < 0.001). Treatment preference in patients
with COPD was statistically different among the phenotypes (p < 0.001). Subgroup analysis was performed in terms of emphysema,
chronic bronchitis and ACO phenotypes of 1107 patients who had thoracic computed tomography. A total of 202 patients had more
than one phenotypic trait, and 149 patients showed no features of a specific phenotype.
Conclusion: Most of the phenotype models have tried to classify the patient into a certain phenotype so far. However, we observed
that some of the patients with COPD had two or more phenotypes together. Therefore, rather than determining which phenotype
the patients are classified in, searching for the phenotypic traits of each patient may enable more effective and individualized
treatment.
Key words: ACO, chronic bronchitis, COPD, emphysema, phenotype
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1. Introduction
Worldwide, 3 million deaths were caused by chronic
obstructive pulmonary disease (COPD) in 2016, and
COPD causes more deaths each year than lung cancer and
human immunodeficiency virus together1. The estimated
overall population prevalence of COPD with Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
Stage II and higher is about 10.1% [1]. Demographic
variables alter the prevalence of COPD by country. The
city of Adana, which is located in the southern region of
Turkey, was included in the Burden of Obstructive Lung
Disease (BOLD) Study and the prevalence of COPD in this
city was reported at an alarmingly high level of 19% [1].
However, another epidemiologic study investigating cases
of physician-diagnosed COPD in the Turkish population
in 2016 revealed the prevalence of COPD as 5.8%.
Additionally, the overall prevalence rates increased from
4.3% in 2012 to 5.8% in 2016, which was a 35% relative
rise [2].
In the last two decades, research on the determination
of phenotypes in COPD to improve treatment efficacy
has increased enormously. However, some difficulties
are still encountered while determining phenotypes: 1.
COPD can be defined as a complex and heterogeneous
disease with several components, as there is a nonlinear
dynamic interaction between them (complex), not all
these components may be present in all patients, and they
may not be seen at all times in one patient (heterogeneous)
[3]. 2. The disease characteristics that can be used to define
phenotypes in COPD include clinical features, imaging,
pulmonary function tests and biomarkers, but integrating
these various characteristics with the aim of determining
phenotypes is challenging. 3. Even the most consensual
phenotypes such as chronic bronchitis, asthma and COPD
overlap (ACO), or emphysema may not be easy to manage,
since considerable overlaps can be seen between them.
We aimed primarily to investigate the distribution of
COPD phenotypes in our study population from Turkey
and to compare the demographics, clinical characteristics
and pharmacological treatment of the patients according
to their phenotypes. The secondary aim of the study was to
discuss the challenges we encountered in dividing patients
into phenotypes. To the best of our knowledge, this is
the first multicenter study presenting the distribution of
COPD phenotypes in Turkey.
2. Material and methods
2.1. Study design and patients
Chronic obstructive pulmonary disease phenotypes in
Turkey “The COPET Study” was designed as a national,
multicenter, observational and cross-sectional study. The

patients were enrolled prospectively between December
2018 and January 2020. Twelve centres (Yedikule Chest
Disease and Chest Surgery Research and Training
Hospital, İstanbul; Gazi University, Ankara; Mersin
University, Mersin; İnönü University, Malatya; İzmir Katip
Çelebi University, İzmir; Dr Suat Seren Chest Disease and
Chest Surgery Research and Training Hospital, İzmir;
Balıkesir University, Balıkesir; Atatürk Chest Disease and
Chest Surgery Research and Training Hospital, Ankara;
Kahramanmaraş Sütçü İmam University, Kahramanmaraş;
Çanakkale On Sekiz Mart University, Çanakkale; Ufuk
University, Faculty of Medicine, Ankara; Selçuk University,
Konya) which may reflect our country in general and 20
researchers who are pulmonary specialists participated
in the study. The center and the number of patients
participating in the study are shown on the map of Turkey
in Figure 1. A sample size of 1145 achieves 99% power
to detect an effect size (W) of 0.2052 using a 9 degrees of
freedom chi-square test with a significance level (alpha) of
0.001 [4]. The study was approved by the ethics committee
of Ufuk University School of Medicine (no. 20190328/4),
and written informed consent was obtained from each
patient.
Patients who met the inclusion criteria were
consecutively recruited in the study when they visited
hospital-based pulmonary outpatient clinics. The inclusion
criteria were as follows: ≥ 40 years of age, COPD diagnosis
for at least a year and confirmed diagnosis of COPD with
a postbronchodilator forced expired volume in 1 s (FEV1)/
forced vital capacity (FVC) < 0.7, current/exsmoker (≥ 10
pack-year smoking history) or a nonsmoker with at least
10 years’ biomass exposure. Patients who did not have a
definitive diagnosis of COPD, had COPD exacerbation
within the past 6 weeks prior to enrolment, were unable
to complete the case report form or who had chronic
respiratory diseases (other than noncystic fibrosis
bronchiectasis, tuberculosis sequelae and asthma) were
excluded from the study. The patients’ demographic and
clinical characteristics were obtained by face-to-face
interviews with the patients and from hospital records.
Pulmonary function tests (PFT) and haemograms
were performed if these were not in the patients’ hospital
records within the last 6 months. The PFT were obtained
using standard equipment according to the American
Thoracic Society/European Respiratory Society consensus
guidelines [5]. The presence of emphysema in thorax
computed tomography (CT) was used to quantify the
extent of emphysema at –950 Hounsfield units and
was confirmed using the local radiologists [6]. COPD
exacerbation was defined as patient reports of increased
symptoms requiring treatment with systemic steroids and/

World Health Organization (2016). Global health estimates [online]. Website http://www.who.int/news-room/fact-sheets/detail/chronic-obstructivepulmonary-disease-(copd) (Accessed November 2018).
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or antibiotics with or without admission to the emergency
department and/or hospitalization2. We recorded only
moderate and severe exacerbations.
We used the POPE study’s algorithm to determine the
COPD phenotypes which is rationale and methodology of
a study to phenotype patients with COPD in Central and
Eastern Europe in a real-life setting [7]. 1) patients who
met the ACO criteria were considered to have the ACO
phenotype; 2) patients with few than two exacerbations
(not requiring hospitalization) in the previous year were
classified as the non-exacerbator phenotype (NON-AE);
3) exacerbators with self-reported chronic cough and
expectoration for more than three months of the year
over two consecutive years were described as frequent
exacerbators with chronic bronchitis (AE-CB); and 4)
the remaining exacerbators were classified as frequent
exacerbators without chronic bronchitis (AE NON-CB)
[7]. ACO was diagnosed when two major criteria or one
major and two minor criteria were met different from
POPE Study. The major criteria included a personal history
of asthma, a positive bronchodilator test (increase in FEV1
≥ 15% and ≥ 400 mL) and eosinophilia in the sputum; the
minor criteria included a personal history of atopy, high
total IgE, and a positive bronchodilator test (increase in
FEV1 ≥ 12% and ≥ 200 mL) [8]. We used peripheral blood
eosinophilia (> 300 cells per mm3) a surrogate marker for
sputum eosinophilia.
2.2. Measurements
Dyspnoea was assessed based on the modified Medical
Research Council (mMRC) dyspnoea scale [9] and also
symptom status was evaluated using the COPD Assessment
Test (CAT) [10]. The postbronchodilator PFT values of each
patient were recorded, and COPD severity was classified
by the predictive FEV1 values: stage 1 (mild), FEV1 ≥ 80%;
stage 2 (moderate), FEV1 ≥ 50% and < 80%; stage 3 (severe),
FEV1 ≥ 30% and < 50%; and stage 4 (very severe), FEV1
< 30% according to the GOLD 2021 recommendations3.
The presence of comorbidities was evaluated by the
Charlson comorbidity index (CCI) [11]. For each patient,
we calculated the age, dyspnoea and airflow obstruction
(ADO) index, which combines age, the mMRC score and
the FEV1. The total score of the ADO index ranges from
zero to 10 points, and a higher score indicates worse
prognosis in patients with COPD [12]. All the patients
were divided into four risk/symptom categories, according
to the GOLD 2021 recommendations: low risk and fewer
symptoms (category A); low risk and more symptoms
(category B); high risk and fewer symptoms (category C);

and high risk and more symptoms (category D). Based
on this categorization, the cut-off points for risk were
exacerbations in the previous year ≥ 2 or ≥ 1 leading to
hospitalization, and the cut-off points for more symptoms
were CAT scores ≥ 10 and/or mMRC ≥ 23.
2.3. Statistical analysis
SPSS 22.0.0 package program (IBM Corporation, Armonk,
NY, USA, 2013) was used in the analysis of the data.
Categorical data were given as number and percentage;
quantitative data were given as median, mean and standard
deviation.
Kolmogorov–Smirnov test was used as normal
distribution test. Kruskal–Wallis test and Mann–Whitney
U test were used in the analysis of quantitative data, and
Pearson chi-square analysis test was used in the analysis of
categorical data. In case the minimum expected value was
below 1 in chi-square analyses or the expected cell number
below 5 was more than 20%, exact correction had been
made. Column comparison was used for posthoc analysis
in categorical data, and Dunn test was used for quantitative
data. A value of p < 0.05 was considered significant.
3. Results
3.1. Demographic and clinical features
A total of 1203 patients were recruited from the study
centers, and 62 patients were excluded because they had
missing data or did not meet the inclusion criteria. A total
of 1141 stable COPD patients with a mean age of 65.8 ± 9
years were included, of whom 87.2% (n = 995) were male.
The rates and numbers of current smokers, exsmokers and
nonsmokers were 32.2% (n = 367), 62.9% (n = 718), and
4.9% (n = 56), respectively. The mean biomass exposure
of all the patients was 34.9 ± 17.6 years. According to the
CCI, 41.1% of patients had at least one comorbidity, and
the three most common comorbidities were heart failure,
diabetes mellitus (DM) and myocardial infarction. The
demographic and clinical features of the patients are given
in Table 1.
3.2. Distribution of phenotypes, GOLD categories and
stages
The NON-AE phenotype was detected at the highest rate
(55.7%; n = 635), followed by the AE NON-CB (25.6%; n =
292), the AE-CB (13.9%; n = 159) and the ACO phenotypes
(4.8%; n = 55). The highest rate of GOLD stage was 2
(42.6%), and the highest GOLD category was D (39.7%).
The distribution of the phenotypes, the GOLD categories
(A–D) and the GOLD stages are shown in Figure 2.

GOLD (2018). Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease
(GOLD) [online]. Website https:// goldcoped.org/ (Accessed July 17, 2018).
2

Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2021). Global strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease 2021 report [online]. Website https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_
WMV.pdfgoldcopd.org/gold-reports/ (Available November 2021)
3
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Table 1. Demographic and clinical characteristics of the patients (n = 1141).
Variables

n (%) or mean ± SD

Age (years)

65.8 ± 9.0

Sex, male

995 (87.2)

BMI (kg/m2)

25.5 ± 4.8

Smoking (package-year)

46.7 ± 24.0

Biomass exposure

496 (43.5)

The time since COPD diagnosis (years)

6.2 ± 4.7

FEV1% predicted

50.9 ± 19.4

FVC % predicted

67.6 ± 20.2

FEV1/FVC

56.3 ± 9.8

CAT score

16.4 ± 9.0

mMRC score

2.0 ± 1.0

More symptomatic according to mMRC or CAT

875 (76.7)

Number of exacerbations in the previous year

1.4±2.2

Number of comorbidities

0.6±0.8

The patients with at least one comorbidity

469 (41.1)

The patients with CHF

167 (14.6)

The patients with DM

152 (13.3)

The patients with MI

105 (9.2)

The patients with malignancy

69 (6.0)

Eosinophil count 10 /mL

199.9 ± 191.6

ADO index

4.1 ± 1.7

3

Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; COPD, chronic
obstructive pulmonary disease; CAT, COPD assessment test; mMRC, modified Medical Research Council; GOLD, Global
initiative for chronic obstructive lung disease; CHF, congestive heart failure; DM, diabetes mellitus; MI, myocardial infarction;
ADO index, age, dyspnea, airflow obstruction index.
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Figure 1. The centers and the number of patients participating in the study.
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3.3. Demographic, clinical and laboratory characteristics
of the patients according to the phenotypes
There were statistically significant differences between
the phenotypes in terms of the PFT values, the CAT and
the mMRC scores, the ADO index, history of smoking,
exacerbation and the eosinophil count and percentage.
The FEV1 value was significantly higher in the ACO
and NON-AE phenotypes than in the AE-CB and
AE NON-CB phenotypes (p < 0.001). The eosinophil
count and percentages were the highest in the ACO
phenotype (p < 0.001). The CAT and the mMRC scores,

the ADO index and the rates of exacerbations in the
previous year were significantly higher in the AE-CB
and NON-CB phenotypes than in the ACO and NONAE phenotypes (p < 0.001). Emphysema was highest in
the AE NON-CB phenotype. There was no difference
between the phenotypes in terms of age, body mass
index (BMI), biomass exposure and the mean number
of comorbidities. However, only DM was highest in the
AE-CB phenotype (p < 0.001). The characteristics of
the COPD patients according to phenotype are given in
Table 2.

Table 2. Comparison of the COPD phenotypes in terms of demographic, clinical and laboratory characteristics.
COPD phenotypes
ACO
n = 55; 4.8%

NON-AE
AE-CB
n = 635; 55.7% n = 159; 13.9%

AE NON-CB
p value
n = 292; 25.6%

Variables

Med (IQR)

Med (IQR)

Med (IQR)

Med (IQR)

Age (years)

65 (9.3)

66 (12)

65 (11.5)

66 (14)

0.138

Education (years)

5 (6)

5 (3)

5 (3)

5 (2.5)

0.012

Smoking (package-year)

46.5 (25.8)

45 (25.5)

40 (25)

48 (27.5)

0.001

BMI (kg/m )

23.5(6.7)

25.5(6)

25 (4.6)

26 (6.8)

0.331

Biomass exposure (year)

38.5(39.5)

36(32)

40 (40)

30 (30)

0.405

The time since COPD diagnosis (years)

5 (4.8)

4 (4.5)

5 (6)

5 (7)

<0.001

FEV1% predicted

54 (26.2)

57 (27.1)

40 (27)

40 (22)

<0.001

CAT score

14 (12)

12(12)

21 (13)

18 (16)

<0.001

mMRC score

2 (1)

2 (1)

3 (1)

2 (1)

<0.001

Eosinophil count 10 /mL

200 (520)

176 (182.5)

160 (240)

130 (180)

<0.001

Eosinophil %

2,7 (3.9)

2 (2.2)

1.8 (2.4)

1.6 (2.4)

<0.001

Number of comorbidities

0 (1)

0 (1)

0 (1)

0 (1)

0.300

Number of exacerbations in the previous year

2 (3.5)

0 (1)

2 (1)

2 (2)

<0.001

ADO index

4 (3.0)

4 (3.0)

5 (2.0)

5 (2.0)

<0.001

2

3

n, (%)
Smoker

15 (27.3)a,b

243 (38.3)b

36 (22.6)a

Exsmoker

35 (63.6)

370 (58.3)

112 (70.4)

201 (68.8)

<0.001

Nonsmoker

5 (9.1)a

22 (3.5)b

11 (6.9)a,b

18 (6.2)a,b

<0.001

Emphysema

20 (40.8)

403 (65.1)

91 (59.5)

246 (86.0)

<0.001

Bronchiectasis

11 (22.4)a

151 (24.4)a

42 (27.5)a

75 (26.2)a

0.806

Hospitalization in the previous year

17 (30.9)

0 (0)

111 (69.8)

193 (66.1)

<0.001

ICU admission in the previous year

8 (14.5)a

0 (0)b

39 (24.5)a

59 (20.2)a

<0.001

ED admission in the previous year

26 (47.3)

107 (16.9)

130 (81.8)

232 (79.5)

<0.001

DM

3 (5.5) a

71 (11.2) a

37 (23.3) b

41 (14.0) a

<0.001

a,b

a

a

a

b

b

b

b

a

c

c

b

<0.001

73 (25.0)a
a

c

c

c

Abbreviations: ACO, asthma-COPD overlap; NON-AE; nonexacerbators; AE-CB, frequent exacerbators with chronic bronchitis;
AE NON-CB, frequent exacerbators without chronic bronchitis; BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity; COPD, chronic obstructive pulmonary disease; CAT, COPD assessment test; mMRC, modified Medical Research
CounciI; GOLD, Global initiative for chronic obstructive lung disease; ICU, intensive care unit, ED, emergency department; DM,
diabetes mellitus. Statistically significant differences between phenotypes were shown as a superscript with symbols a, b, c, d.
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3.4. Pharmacological treatment usage rates by COPD
phenotypes
Long-acting muscarinic antagonists (LAMAs) were
preferred more in the NON-AE phenotype, long-acting
β-agonists (LABAs) in the ACO and NON-AE phenotypes,
LABA + inhaled corticosteroid (ICS) in the ACO
phenotype and LABA + LAMA + ICS (triple therapy) in
the AE-CB and AE NON-CB phenotypes (Table 3).

3.5. Venn diagrams of COPD
The patients with thorax CT (n = 1107) are shown in a
Venn diagram. Seven hundred and sixty patients (68.7%)
had emphysema, 345 patients (31.2%) had chronic
bronchitis, and 49 patients (4.2%) had ACO, according
to the clinical, laboratory and radiological characteristics.
A total of 149 patients (13.5%) did not have any of these
phenotypes (Figure 3).

Table 3. Pharmacological treatment usage rates by COPD phenotypes.
COPD Phenotypes
Inhalers drugs
n (%)

ACO
n = 55 (4.8%)

NON-AE
n = 635 (55.7%)

AE-CB
n = 159 (13.9%)

AE NON-CB
n = 292 (25.6%)

LAMA

5 (9.1)a,b

110 (17.3)b

7 (4.4)a

14 (4.8)a

LABA

5 (9.1)a

67 (10.6)a

3 (1.9)b

6 (2.1)b

LAMA+LABA

6 (10.9)

109 (17.2)

7 (4.4)

31 (10.6)a

LABA+ICS

23 (41.8)a

102 (16.1)b

34 (21.4)b

LAMA+LABA+ICS

15 (27.3)

230 (36.2)

102 (64.2)

179 (61.3)b

SABA+SAMA+ICS

1 (1.8)a

11 (1.7)a

6 (3.8)a

10 (3.4)a

SABA+SAMA

0 (0.0)a

6 (0.9)a

0 (0.0)a

0 (0.0)a

Theophyllin

3 (42.9)a

31 (50.0)a

12 (60.0)a

37 (53.6)a

Mucolytic

0 (0.0)

25 (40.3)

1 (5.0)

26 (37.7)b

Roflumilast

0 (0.0)a

1 (1.6)a

1 (5.0)a

Mucolytic + Theophyllin

1 (14.3)

4 (6.5)

6 (30.0)

5 (7.2)

LTA

3 (42.9)

1 (1.6)

0 (0.0)

0 (0.0)b

a,b,c

c

a

b

a

<0.001

52 (17.8)b
b

p

Additional drugs
a

b

a,b,c

a

c

a

b

b

<0.001

1 (1.4)a
b

a,c

Abbreviations: COPD, chronic obstructive pulmonary disease; ACO, asthma-COPD overlap; NON-AE, nonexacerbators; AE-CB,
frequent exacerbators with chronic bronchitis; AE NON-CB, Frequent exacerbators without chronic bronchitis; LAMA, long acting
muscarinic antagonist; LABA, long acting beta agonist; ICS: inhaled corticosteroid; SABA, short acting beta agonist; SAMA, short
acting muscarinic antagonist; LTA, leukotriene antagonist. Data are presented as number (%). Statistically significant differences
between phenotypes were shown as a superscript with symbols a, b, c, d.

Phenotype
25%

15% 7%

56%

14%

NON - AE

GOLD Stage

5%

GOLD
20% 3%

43%

35%

AE - CB

AE NON - CB

ACO

Stage 2

Stage 3

40%

37%

Stage 4

Stage 1

D

B

A

C

Figure 2. Distribution of phenotypes, GOLD stages and GOLD categories (A–D) in COPD patients. Abbreviations: NON-AE,
nonexacerbators; AE NON-CB, frequent exacerbators without chronic bronchitis; AE-CB, frequent exacerbators with chronic
bronchitis; COPD, chronic obstructive pulmonary disease; ACO, asthma-COPD overlap; GOLD, Global initiative for chronic
obstructive lung disease; FEV1, forced expiratory volume in 1 s (% predicted).
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Figure 3. Venn diagram of chronic obstructive pulmonary disease
(COPD). The total number of patients 1107. ACO, asthma-COPD overlap.

4. Discussion
This study indicates that the NON-AE phenotype is the
most prevalent (55.7%), followed by the AE NON-CB
(25.6%), AE-CB (13.9%) and ACO (4.8%) phenotypes.
NON-AE is also the most commonly observed COPD
phenotype in other countries of the world [4,13–15]. While
AE NON-CB was the second most common phenotype in
our study, it was reported to be the AE-CB phenotype in
other regions [4,13–15]. This difference may be caused by
genetic or environmental factors. The ACO phenotype was
observed at the lowest rate (4.8%), which is in concordance
with other countries, as ACO rates ranged from 5% to 15%
in separate studies [4,13–15]. We used the POPE study’s
criteria, which suggests categorizing patients with frequent
exacerbations into two phenotypes: AE-CB and AE NONCB [6]. We found the highest rate of emphysema among
the AE NON-CB (86%) phenotype. This indicated that the
predominant condition in the AE NON-CB phenotype
was emphysema. In our study, almost 3.5% of the patients
who were frequent exacerbators did not have chronic
bronchitis or emphysema. Similarly, a small proportion
of patients (2.3%) remained unclassified in the CHAIN
Cohort [16]. Hence, although this phenotype algorithm is
simple, clinically relevant and easily applicable, it may not
fully meet the needs of some patients.
There were statistically significant differences amongst
the phenotypes in terms of clinical laboratory and
radiological characteristics in our study. The patients
with the AE-CB and NON-CB phenotypes were more
symptomatic and had worse lung function parameters,
similar to the POPE study’s results [17]. The ADO index,
which seems to have medium- and long-term predictive
prognostic reliability [12], was higher in the AE-CB and

1136

the NON-CB phenotypes than in the ACO and NONAE. The rates of exacerbations in the previous year
were significantly higher in the AE-CB and NON-CB
phenotypes compared to the other phenotypes. Our
results are similar to the literature; in the PLATINO
Study, the subjects with chronic bronchitis had worse lung
function and general health status and more respiratory
symptoms, physical activity limitation and exacerbations
[18]. Frequent exacerbators with the chronic bronchitis
phenotype were the most symptomatic patient, with a
higher BODE (BMI, airway obstruction, dyspnea, exercise
capacity) score, in the CHAIN Cohort [16]. The number
of current smokers in the NON-AE phenotype, the
exsmokers in the frequent exacerbators phenotype and
the nonsmokers in the ACO phenotype were significantly
higher compared to the other phenotypes. The quantity of
cigarettes smoked (pack-years) was significantly higher in
the AE NON-CB than in the ACO and NON-AE in our
study. Similarly, the Polish subcohort of the POPE study
found that smoking habits differ among the phenotypes.
There were fewer current smokers in the AE-CB compared
to the ACO and NON-AE phenotypes, and the AE-CB
phenotype group smoked more cigarettes compared to the
ACO phenotype group [13]. The POPE study showed that
patients with ACO were younger on average, had a higher
BMI and were more likely to be female compared to the
other phenotypes [17]; we found no difference between
the phenotypes in terms of age, sex, BMI and biomass
exposure. Previous study found that 97.7% of COPD
patients had one or more reported comorbidities [19]. We
detected one comorbidity in at least 41.1% of the subjects,
according to the patients’ self-reports. This difference may
be a result of unrecorded some common comorbidities in
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our study, such as hypertension, anxiety and depression,
which are not included in the CCI. There were no
differences amongst the phenotypes in terms of the mean
number of comorbidities, but DM was the highest in the
AE-CB phenotype in our study. Similarly, comorbidities
were measured by the CCI in both the CHAIN cohorts
and the Polish subcohort of the POPE study, and there
were no differences amongst the phenotypes [13,16].
We found that the pharmacological treatment
preferences for COPD were statistically different between
the phenotypes. The most commonly observed agents were
bronchodilators in the NON-AE, LABA + ICS in the ACO
and triple inhaler therapies in the frequent exacerbator
phenotypes. Even though the patients in our cohort were
not treated according to their phenotypes, the physicians
seemed to take into account phenotype-based therapy in
clinical practice. By contrast, 29.1% of patients with ACO
were not receiving ICS, despite the benefits that ICS has
demonstrated in this group of patients. Similarly, in other
countries, it has been observed that treatment patterns
differ among the phenotypes and ICS has not been used
as widely as expected in the ACO phenotype [14,16,17].
We performed subgroup analysis in 1107 patients
with thorax CT, 202 patients (18.3%) had two or more
phenotypic features (emphysema ± chronic bronchitis ±
ACO). Our results support the idea that the phenotypes
could coexist in some patients at the same time. In
contrast, 149 patients (13.5%) could not be classified by
any phenotype. We think that some phenotypes caused
by pathophysiological changes such as emphysema,
chronic bronchitis, or bronchiectasis are permanent
(they may be categorized as fixed phenotypes), while
some phenotypes, such as frequent exacerbator or more
symptomatic phenotypes, which may change over the
course of the disease (they may be categorized as variable
phenotypes). In follow-up, evaluating fixed and variable
phenotypes together in each patient may enable more
effective management, not only for those with frequent
exacerbations but also for patients with phenotypes that
are more symptomatic without frequent exacerbation.

This study has some limitations. First, all the centers
participating in the study were pulmonary outpatient
clinics of a university or training hospital, which may have
led to the recruitment of more severe patients. However,
as there is no referral chain to tertiary care hospitals in
our country, patients with stage 1 and category A could
also have been enrolled in the study. Also, our results
may not reflect Turkey in general, however, we think
that the inclusion of big cities such as İstanbul, Ankara
and İzmir, which have received immigration from all
over the country, reduces this bias. Second, the patients’
PFTs and laboratory and radiology results were recorded
retrospectively, if present, in their previous follow-ups.
Finally, the study had a cross-sectional design, meaning
that the patients’ medical histories, such as exacerbations,
comorbidities and exposures were recorded retrospectively
based on patient statements and hospital records, which
may potentially lead to recall bias.
In conclusion, this study provides important data for
future studies regarding the distribution, characteristics and
pharmacological treatment of predefined COPD phenotypes
in the Turkish population. Additionally, our results support
the fact that there are some dilemmas when defining COPD
phenotypes. We consider that, rather than determining
which phenotype the patients are classified in, searching for
the phenotypic characteristics of each patient may enable
more effective and individualized use of pharmacological
and nonpharmacological treatment options.
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